{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:38:31Z","timestamp":1771663111761,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A new formulation of once daily extended-release tacrolimus (LCP-tac, Envarsus XR) was approved for use in the USA for kidney transplant recipients in 2015. There are limited data regarding real-world observations with conversion to LCP-tac in liver transplant recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective analysis of liver transplant recipients treated with LCP-tac. Data collection included (1) reasons for switching to LCP-tac; (2) conversion ratio used; (3) kidney function at time of conversion and 3\u2009months after; (4) outcomes of conversion [acute cellular rejection rates and cytomegalovirus (CMV) viremia] within 3\u2009months of conversion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Average conversion ratio used to achieve therapeutic drug level without further dose adjustment was 1:0.73 (SD 0.11). Median time after transplant was 508\u2009days (IQR 736). Common reasons patients were switched to LCP-tac were from fluctuations in tacrolimus levels (44%) and adverse effect of tremor (32%). Among patients who were switched due to tremors 88% noted significant improvement. There was no difference in serum creatinine (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.55) or glomerular filtration rate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.64) from baseline to 3\u2009months postconversion. There were no episodes of acute cellular rejections or CMV viremia postconversion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This observational study demonstrated that conversion of immediate-release tacrolimus to LCP-tac in liver transplant recipients was well tolerated and effective.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002172","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T16:14:10Z","timestamp":1620576850000},"page":"1124-1128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients"],"prefix":"10.1097","volume":"33","author":[{"given":"David","family":"Choi","sequence":"first","affiliation":[{"name":"University of Illinois at Chicago College of Pharmacy"},{"name":"Department of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarang","family":"Thaker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"West-Thielke","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplant, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annesti","family":"Elmasri","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chan","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients.","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transplant"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.","volume":"96","author":"Gaber","year":"2013","journal-title":"Transplantation"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ctr.12581","article-title":"Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.","volume":"29","author":"Langone","year":"2015","journal-title":"Clin Transplant"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/lt.23844","article-title":"Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.","volume":"20","author":"Alloway","year":"2014","journal-title":"Liver Transplant"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cpdd.657","article-title":"Pharmacokinetics of once-daily extended-release tacrolimus tablets versus twice-daily capsules in de novo liver transplant.","volume":"8","author":"DuBay","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/lt.22211","article-title":"Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial.","volume":"17","author":"Fischer","year":"2011","journal-title":"Liver Transpl"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American Kidney transplant recipients.","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3748\/wjg.v24.i16.1795","article-title":"High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation.","volume":"24","author":"Del Bello","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes.","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ajt.15199","article-title":"Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values.","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S149906","article-title":"Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients.","volume":"12","author":"Choi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R15-20250801","first-page":"9096435","article-title":"Tacrolimus toxicity due to biliary obstruction in a combined kidney and liver transplant recipient.","volume":"2017","author":"Chan","year":"2017","journal-title":"Case Rep Transplant"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4236\/ijcm.2013.410078","article-title":"Effects of cholestasis on whole blood concentration of tacrolimus, an immunosuppressant, in living-related liver transplant recipients.","volume":"04","author":"Kobuchi","year":"2013","journal-title":"Int J Clin Med"},{"key":"R17-20250801","first-page":"1012","article-title":"Effects on pharmacokinetics of tacrolimus in liver transplant patients.","volume":"2","author":"Zhang","year":"2016","journal-title":"SM J Pharmac Ther"},{"key":"R18-20250801","first-page":"2736","article-title":"Pharmacokinetics of FK 506 in transplant patients.","volume":"23","author":"Venkataramanan","year":"1991","journal-title":"Transplant Proc"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8101586","article-title":"A low tacrolimus concentration\/dose ratio increases the risk for the development of acute.","volume":"8","author":"Th\u00f6lking","year":"2019","journal-title":"J Clin Med"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1097\/TP.0000000000002700","article-title":"Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): an extension study.","volume":"103","author":"Adam","year":"2019","journal-title":"Transplantation"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:09:53Z","timestamp":1754068193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002172","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}